Understand the source comparison
Cagrilintide Help Blood Sugar Research: Mechanism Comparison
Primary Receptor Target Calcitonin and amylin receptors (CTR, AMY1-3) GLP-1 receptors in pancreas and hypothalamus Insulin receptors on muscle, liver, adipose tissue Cagrilintide operates through an entirely separate pathway. Combining it with GLP-1 agonists a
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Primary Receptor Target
- Calcitonin and amylin receptors (CTR, AMY1-3)
- GLP-1 receptors in pancreas and hypothalamus
- Insulin receptors on muscle, liver, adipose tissue
- Cagrilintide operates through an entirely separate pathway. Combining it with GLP-1 agonists addresses complementary mechanisms
- Effect on Gastric Emptying
- Delays gastric emptying by 40–50%, reducing glucose absorption rate
- Moderate delay (20–30%). Secondary to appetite suppression
- No direct effect on gastric motility
- Cagrilintide produces the strongest gastric delay of any approved metabolic peptide
- Glucagon Suppression
- Direct suppression of postprandial glucagon release
- Indirect suppression through enhanced insulin secretion
- No direct effect on glucagon
- Cagrilintide's glucagon suppression persists even in insulin-deficient states
- HbA1c Reduction
- 1.0–1.2% reduction as monotherapy
- 1.5–2.0% reduction as monotherapy
- 1.5–2.5% reduction depending on dosing
- Cagrilintide monotherapy is less potent than GLP-1 agonists but synergistic when combined
- Weight Loss Effect
- 6–11% body weight reduction (dose-dependent)
- 10–15% body weight reduction (dose-dependent)
- Typically causes weight gain (2–4 kg)
- Cagrilintide's weight loss is driven by satiety signaling and gastric delay. Not insulin-mediated fat storage
- Dosing Frequency
- Once weekly (half-life ~7 days)
- Once weekly (semaglutide, tirzepatide)
- Multiple daily injections or continuous infusion
- Weekly dosing improves research protocol adherence and reduces injection-site variability